Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

New two-part phase I trial with ThGLP-1

Oct. 15, 2004

Positive preliminary results for phase I study of oral PTH

Oct. 15, 2004

DX-88 granted fast track designation for HAE

Oct. 15, 2004

Novel PEPCK inhibitors prepared and tested at Roche

Oct. 15, 2004

Two series of glucokinase activators reported by OSI scientists

Oct. 15, 2004

Statins may promote new bone formation via induction of PI3K signaling pathway

Oct. 15, 2004

Orally active cathepsin K inhibitor prevents bone loss in vitro and in vivo

Oct. 14, 2004

Norditropin NordiFlex receives FDA approval

Oct. 14, 2004

Diamyd studied in type 2 diabetes patients in Sweden

Oct. 14, 2004

Beta-blocking drugs reduce risk of fractures

Oct. 13, 2004

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 22, 2026.
‘Detargeted’ targeted gene therapy improves activity in Pompe
BioWorld
A new strategy aims to improve gene therapy for Pompe disease by optimizing both the genetic component that restores the function of a deficient lysosomal enzyme...
Roche reports new TREM2 agonists
BioWorld Science
F. Hoffmann-la Roche Ltd. and Hoffmann-La Roche Inc. have identified new triggering receptor expressed on myeloid cells 2 (TREM2) agonists potentially useful for...
Genescience presents STAT6 degrader for atopic dermatitis
BioWorld Science
Genescience Pharmaceutical Co. Ltd. has presented data on a new STAT6 PROTAC degrader – GenSciP166 – which selectively targets STAT6 for proteasomal degradation....
Recludix’s first-in-class STAT6 inhibitor shows efficacy in atopic dermatitis
BioWorld Science
Researchers from Recludix Pharma Inc. reported preclinical efficacy data on REX-8756 (SAR-448755), a first-in-class orthosteric STAT6 inhibitor in models of...